The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.

70 , 78 More recently, the GeoMETry-III phase III trial comparing capmatinib to standard-of-care docetaxel in previously treated MET ex14 NSCLC showed numerical differences in ORR (53.3% vs 0%) and PFS (6.1 vs 4.1 months; hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.16–1.3, p = 0.066) that although consistent with GEOMETRY mono-1 results did not reach statistical significance after early trial termination. 79 Tepotinib was the second selective MET inhibitor to receive accelerated approval for MET ex14 NSCLC in February 2021 based on initial results from the large phase II VISION trial. 201 Updated results confirmed initial findings with frequent and durable resp

also in 111,027 other papers